Further comprehension of the GLP-1 pathway in ALS pathophysiology could provide valuable insights into potential therapeutic interventions targeting this pathway to attenuate disease progression and mitigate symptoms. This evidence concerns the gene GCG and amyotrophic lateral sclerosis.